Peng Minghui, Zheng Zhuifeng, Chen Shaoyang, Fang Le, Feng Rongxiu, Zhang Lijun, Tang Qingnan, Liu Xuewen
Department of Oncology, Third Xiangya Hospital, Central South University, Changsha, China.
Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.
Front Oncol. 2022 May 23;12:908031. doi: 10.3389/fonc.2022.908031. eCollection 2022.
To explore the impacts of AE (aloe-emodin) in gefitinib-resistant NSCLC (non-small cell lung cancer) cells and the corresponding mechanism.
PC9 and PC9-GR cells were cultured and treated by gefitinib, AE, or the combination of the two drugs. Then, viability, apoptosis, migration and invasion of cells were investigated using CCK-8, TUNEL, wound healing assay, and transwell assay, respectively. Female BALB/c nude mice were employed for the establishment of xenograft tumor models to examine the role of AE in tumor growth.
PC9-GR cells showed reduced apoptosis and enhanced cell viability, migration and invasion upon treatment by gefitinib, compared with PC9 cells. E-cahherin in PC9-GR cells was down-regulated, while Vimentin, Snail2 (or Slug) and Twist1 in PC9-GR cells were up-regulated, compared with PC9 cells. Meanwhile, treatment by a combination of gefitinib and AE significantly strengthened apoptosis of PC9-GR cells, while attenuated their migration and invasion, compared with the control group or treatment by gefitinib or AE alone. WB results showed that AE could reverse EMT and activation of PI3K/AKT signalling pathway in PC9-GR cells. experiments showed that tumor growth and EMT of PC9-GR cells were dramatically repressed after treatment by a combination of AE and gefitinib. Additionally, the use of SC97 (a PI3K/Akt pathway activator) could counteract the effects of AE in gefitinib-resistant PC9 cells.
AE could enhance the gefitinib sensitivity of PC9-GR cells and reverse EMT by blocking PI3K/Akt/TWIS1 signal pathway.
探讨芦荟大黄素(AE)对吉非替尼耐药的非小细胞肺癌(NSCLC)细胞的影响及其相应机制。
培养PC9和PC9-GR细胞,分别用吉非替尼、AE或两种药物联合处理。然后,分别采用CCK-8法、TUNEL法、划痕愈合试验和Transwell试验检测细胞的活力、凋亡、迁移和侵袭能力。采用雌性BALB/c裸鼠建立异种移植瘤模型,以研究AE在肿瘤生长中的作用。
与PC9细胞相比,吉非替尼处理后的PC9-GR细胞凋亡减少,细胞活力、迁移和侵袭能力增强。与PC9细胞相比,PC9-GR细胞中的E-钙黏蛋白下调,而波形蛋白、Snail2(或Slug)和Twist1上调。同时,与对照组或单独使用吉非替尼或AE处理相比,吉非替尼与AE联合处理显著增强了PC9-GR细胞的凋亡,同时减弱了其迁移和侵袭能力。蛋白质免疫印迹结果显示,AE可逆转PC9-GR细胞中的上皮-间质转化(EMT)和PI3K/AKT信号通路的激活。体内实验表明,AE与吉非替尼联合处理后,PC9-GR细胞的肿瘤生长和EMT受到显著抑制。此外,使用SC97(一种PI3K/Akt途径激活剂)可以抵消AE对吉非替尼耐药的PC9细胞的作用。
AE可通过阻断PI3K/Akt/TWIS1信号通路增强PC9-GR细胞对吉非替尼的敏感性并逆转EMT。